Fluorodopa F 18

DRUG6 trials

Conditions

Congenital HyperinsulinismGlioblastomaGliomaInsulinomaMalignant Brain NeoplasmMalignant GliomaRecurrent Soft Tissue SarcomaResectable Soft Tissue Sarcoma

Early Phase 1

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

RecruitingNCT07025226

Mayo ClinicGlioma

Start: 2025-08-12End: 2027-09-01Target: 10Updated: 2026-01-26

Phase 1

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

RecruitingNCT02021604

Cook Children's Health Care SystemCongenital Hyperinsulinism, Insulinoma

Start: 2013-10-09End: 2028-06-30Target: 250Updated: 2024-07-16

Phase 2

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

CompletedNCT03778294

Mayo ClinicGlioblastoma, Malignant Glioma

Start: 2019-03-28End: 2023-11-26Updated: 2025-07-03

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Active, not recruitingNCT05781321

Mayo ClinicGlioblastoma

Start: 2023-03-23End: 2028-07-02Target: 170Updated: 2026-02-03

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Not yet recruitingNCT06667726

Mayo ClinicMalignant Brain Neoplasm

Start: 2026-10-01End: 2029-10-08Target: 47Updated: 2026-03-16

Unknown Phase

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

CompletedNCT05560009

Mayo ClinicRecurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma

Start: 2022-11-10End: 2024-07-09Updated: 2025-07-10

Related Papers

Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.

2024-11-188 citations

Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma.

2024-04-096 citations

Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.

Journal of Clinical Oncology2023-06-015 citations